Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
9.1.2020 15:00:00 EET | Business Wire | Press release
Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim’s leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company’s extensive range of therapeutic antibodies targeting this pathway.
“The impressive preclinical studies at Enleofen have revealed the potential of IL-11 blockade to treat a broad range of diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “We are excited to have these monoclonal antibodies in our pipeline and have the opportunity to accelerate their path to many patients whose needs are not met by current treatments.”
IL-11 is a cytokine, a protein certain cells of the body use to communicate, and plays a key role in fibro-inflammatory conditions. Blocking IL-11 action has been shown to inhibit disease across many organs (liver, lung, kidney, retina, bowel, heart and skin). In preclinical studies, antibody-based IL-11 antagonists were able to prevent and reverse inflammation and fibrosis, and restore organ function.
Enleofen is a spin out company from the National Heart Centre Singapore (NHCS) at SingHealth and Duke-NUS Medical School under the SingHealth Duke-NUS Academic Medical Centre (AMC), Singapore and exclusively licensed a suite of patents and number of antibody products when it was founded in 2017, from the AMC. Subsequent to this, Enleofen has built an extensive anti-IL-11 antibody platform and advanced its drug development programs towards the clinic. Boehringer Ingelheim will now develop this platform further and plans to work jointly with scientists at the AMC to accelerate the platform into clinical development. The initial focus will be on novel therapies for patients with NASH and ILDs, two of Boehringer Ingelheim’s core disease focus areas, with a potential to expand into further fibro-inflammatory conditions based on IL-11’s central role in disease.
“Enleofen is very excited to engage Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D to develop further anti-IL-11 therapies to begin to address the unmet medical needs of patients worldwide,” said Prof Stuart Cook, Director and co-founder of Enleofen. “The preclinical data across a range of conditions are unprecedented and this new approach of targeting IL-11 could be a game changer”.
The acquisition of the IL-11 program from Enleofen strengthens Boehringer Ingelheim’s pipeline portfolio, which combines approaches that are effective across multiple fibrotic diseases with disease-specific approaches to achieve greater therapeutic effect and builds on the experience gained with nintedanib in fibrotic lung diseases. Boehringer Ingelheim will be solely responsible for the clinical, regulatory and commercial development of the licensed therapies. Under the terms of the agreement, Enleofen may receive earn out payments in excess of one billion USD per product in upfront and success-based development and commercialization milestones.
For references and notes to editors, please visit:
http://www.boehringer-ingelheim.com/press-release/fibrotic-diseases-partnership-enleofen
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005346/en/
Contact information
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
linda.ruckel@boehringer-ingelheim.com
Enleofen
Charu Srivastava
charu@redhill.asia
+65 91810614
Mariyam Haider
mariyam@redhill.asia
+65 86056752
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research11.9.2026 15:00:00 EEST | Press release
Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier, an independent international pharmaceutical group governed by a foundation, to license K Pro, Owkin’s AI Scientist, together with multimodal patient data to advance the company’s oncology research. Under the agreement, Owkin will make multimodal patient data from its MOSAIC network accessible for analysis to Servier’s research teams, within K Pro. This agreement is the next chapter in Owkin and Servier’s collaboration, their previous work together being in patient subgroup identification, also in oncology. K Pro is Owkin’s AI scientist. It brings multimodal patient data and specialized biological agentic AI to drive smarter and faster decision-making to each step of the pharmaceutical value chain. K Pro utilizes specialized biological tools, leveraging a decade of knowledge gained through pharmaceutical partnerships and st
Mohammed bin Rashid Al Maktoum Global Water Award Accepts Entries Until 30 September 202611.9.2026 11:09:00 EEST | Press release
The Mohammed bin Rashid Al Maktoum Global Water Award continues to attract strong interest from innovators, researchers and institutions worldwide as it enters the final phase of its fifth cycle. Overseen by the UAE Water Aid Foundation (Suqia UAE) under the umbrella of the Mohammed bin Rashid Al Maktoum Global Initiatives and with a total prize value of USD 1 million, the award promotes the development of sustainable solutions that help tackle water scarcity and improve access to safe water, particularly in communities most affected by water shortages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260911305420/en/ HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of Suqia UAE (Photo: AETOSWire) Applicants are encouraged to submit comprehensive information about their submissions, thereby helping the judging panel evaluate the various stages and mechanisms of their innovation, including water production, treatme
SES Launches New Content Orchestration and Hybrid Delivery Platform11.9.2026 08:30:00 EEST | Press release
SES today announced the launch of SES CORE, the first-of-its-kind content orchestration and hybrid delivery platform, designed to enable broadcasters and media customers to manage, monitor, and enable transmission of content seamlessly via satellite, fiber, and IP. Built on infrastructure-neutral architecture, SES CORE provides a single user interface for content delivery. By bringing multiple distribution technologies into a unified orchestration layer, the platform enables customers to select the most effective content delivery path, guaranteeing service reliability and consistent delivery of high-quality content to global partners. Through SES CORE, customers gain real-time visibility into service status by monitoring active content feeds. The platform provides network performance insights, automates operational tasks, and offers redundancy options. Together, those capabilities help broadcasters to manage content distribution more independently and efficiently, simplify operations a
Ant International's Agentic Mobile Protocol Rolls Out Globally with Wallets and Acquirers; Initiating Collaboration on KYA Interoperability Framework with Mastercard and Visa11.9.2026 06:26:00 EEST | Press release
As Ant International builds out its Agentic Mobile Protocol (AMP) with deeper interoperability and open-source initiatives, fintech and payment leaders are deploying the protocol globally at an accelerated pace, to enable trusted agentic transactions in large-scale commercial scenarios. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910162444/en/ Ant International's Agentic Mobile Protocol is rolling out across the global mobile payment ecosystem Towards building the World's Largest Agentic Payment Network The AI economy is built on the ability of the financial industry to ensure AI agents interact to make decisions and execute transactions end-to-end for consumers and businesses, securely, smoothly and with full authorisation across all payment rails, especially in prevalent mobile payment scenarios through QR scans, card swipes or phone taps. Launched in April 2026, the AMP is an open payment protocol built by Ant Inter
Peter Rauch Named President of Mountain Hardwear11.9.2026 02:00:00 EEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Peter Rauch will be the new President of the Mountain Hardwear brand. Mountain Hardwear's mission is to encourage and equip people to seek wilder paths. With over 30 years of wild wisdom, Mountain Hardwear continues to offer premium technical apparel, accessories and equipment products for climbers, mountaineers, skiers, snowboarders, and trail athletes. Troy Sicotte will transition to a new role as Global Vice President, Sales for Mountain Hardwear. Mr. Rauch transitions from his current role as General Manager of Columbia Brand North America and brings nearly 20 years of leadership experience across the Columbia family of brands, deep industry knowledge and a genuine passion for the outdoors. "Throughout his career, Peter has built strong cross-functional partnerships, developed high-performing teams, and delivered meaningful business re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom